USPSTF Finds Evidence Lacking to Prevent Illicit Drug Use in Youth
TUESDAY, Oct. 1, 2019 -- The U.S. Preventive Services Task Force (USPSTF) finds that the current evidence is insufficient to recommend primary care-based interventions to prevent illicit drug use in children, adolescents, and young adults. These findings form the basis of a draft recommendation statement published online Oct. 1 by the USPSTF.
Elizabeth O'Connor, Ph.D., from the Kaiser Permanente Center for Health Research in Portland, Oregon, and colleagues conducted a systematic review of primary care-relevant interventions to prevent illicit and nonmedical drug use in children, adolescents, and young adults. Twenty-five trials with 17,482 individuals were included in the review.
The researchers found that in 16 of the general prevention trials, health outcomes were reported, but no single outcome was widely reported and no group differences were seen in most trials. Illicit and nonmedical drug use was reduced by some of the general prevention interventions, but the results were inconsistent across the literature, with no statistically significant association for illicit drug use. Based on these findings, the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of primary care-based behavioral counseling interventions to prevent or reduce illicit drug use among children, adolescents, and young adults (I statement).
"It is critical to find effective ways for clinicians to keep children and teens from starting to use drugs in the first place," USPSTF member Michael Silverstein, M.D., M.P.H., said in a statement.
© 2020 HealthDay. All rights reserved.
Posted: October 2019
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.